{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:26:15Z","timestamp":1763699175753,"version":"3.45.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cllc.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:56:51Z","timestamp":1756223811000},"page":"680-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-4204","authenticated-orcid":false,"given":"Noah H","family":"Richardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser H","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misty D","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cllc.2025.08.015_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"18","author":"Kwak","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2025.08.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus Crizotinib in patients with advanced ALK -positive non\u2013Small cell lung cancer: 5-year outcomes from the phase III CROWN study","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.cllc.2025.08.015_bib0003","first-page":"1","article-title":"Advances in the management of Central nervous system metastases in non-small cell lung cancer","volume":"23","author":"Avila","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.015_bib0004","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.08.015_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of Central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.08.015_bib0006","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.08.015_bib0007","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.015_bib0008","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jtho.2021.12.011","article-title":"Continuation of Lorlatinib in ALK-positive NSCLC beyond progressive disease","volume":"17","author":"Ou","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.08.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.04.012","article-title":"Intracranial response of ALK+ non-small-cell lung cancer to second-line dose-escalated Brigatinib after alectinib discontinuation due to drug-induced Hepatitis and relapse after whole brain radiotherapy followed by stereotactic radiosurgery","volume":"22","author":"Urbanska","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2025.08.015_bib0010","article-title":"Efficacy and safety of dose-escalated Alectinib in patients with metastatic ALK-positive NSCLC and Central nervous system relapse on standard-dose alectinib","volume":"5","author":"Cheung","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"10.1016\/j.cllc.2025.08.015_bib0011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.08.015_bib0012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in Non\u2013Small-Cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"JOP"},{"issue":"6","key":"10.1016\/j.cllc.2025.08.015_bib0013","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat Cancer"},{"issue":"22","key":"10.1016\/j.cllc.2025.08.015_bib0014","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-19-1436","article-title":"Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cllc.2025.08.015_bib0015","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:22:52Z","timestamp":1763698972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425002232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525730425002232"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.015","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}